Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RBP4 | P02753 | 1/20 | 0.46 |
| ▸ | PHGDH | O43175 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | LIPE | Q05469 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10280123 | 1.00 | ALDH1A1 (0.56) | ALDH1A1KMT2AMEN1NPC1RBP4 | |
| SCHEMBL14417829 | 1.00 | ALDH1A1 (0.56) | ALDH1A1KMT2AMEN1NPC1RBP4 | |
| SCHEMBL10232869 | 0.81 | ALDH1A1 (0.41) | ALDH1A1KMT2AMEN1RBP4 | |
| SCHEMBL10328210 | 0.81 | ALDH1A1 (0.41) | ALDH1A1KMT2AMEN1RBP4 | |
| SCHEMBL595967 | 0.81 | GNAI3 (0.40) | ALDH1A1KMT2AMEN1RBP4 | |
| SCHEMBL595966 | 0.81 | GNAI3 (0.40) | ALDH1A1KMT2AMEN1RBP4 | |
| SCHEMBL14417814 | 0.81 | GNAI3 (0.40) | ALDH1A1KMT2AMEN1RBP4 | |
| SCHEMBL15247215 | 0.79 | EPHX2 (0.39) | ALDH1A1KMT2AMEN1RBP4GAA | |
| SCHEMBL13438120 | 0.78 | ALDH1A1 (0.68) | ALDH1A1KMT2AMEN1NPC1PHGDH | |
| SCHEMBL12788667 | 0.77 | ALDH1A1 (0.51) | ALDH1A1KMT2AMEN1NPC1PHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178744-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-07-12 | — | — | US | disclosed |
| US-7268150-B2 | 2-cyano-4-fluoropyrrolidine derivative or its salt | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-11 | — | — | US | disclosed |
| US-7268150-B2 | 2-cyano-4-fluoropyrrolidine derivative or its salt | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178744-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | MTOR, RICTOR, RPTOR | ALDH1A1 4261/4885KMT2A 1587/4885MEN1 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.